Explore

Canada and EU should ally to protect democracies, Carney says, after 'associate member' proposal angers Trump

Canada and EU should ally to protect democracies, Carney says, after 'associate member' proposal angers Trump

By Ingrid Melander, Charlotte Van Campenhout and Yves Herman STRASBOURG, Sept 17 (Reuters) - Canada and Europe should ally to protect their markets, democracies and rule of law in a world dominated by the United States and China, Prime Minister Mark Carney said on Thursday, after an EU proposal to

Sling Therapeutics Secures $123 Million for Thyroid Eye Disease Drug Trial

Sling Therapeutics Secures $123 Million for Thyroid Eye Disease Drug Trial

Sling Therapeutics Secures $123 Million for Thyroid Eye Disease Drug Trial

Eli Lilly Receives FDA Approval for Combination Breast Cancer Therapy

Eli Lilly Receives FDA Approval for Combination Breast Cancer Therapy

Eli Lilly's oral selective estrogen receptor degrader (SERD) imlunestrant (Inluriyo) has secured a second FDA approval, this time for use in combination with the CDK4/6 inhibitor abemaciclib (Verzenio), another drug from Lilly. This combination therapy is approved for ER-positive, HER2-negative breast cancer patients with ESR1 mutations whose disease has progressed after at least one line of endocrine therapy. The approval follows results from the phase 3 EMBER-3 trial, which demonstrated that the combination therapy doubled the median progression-free survival (PFS) to 11 months, compared to five and a half months for Inluriyo alone. According to Jacob Van Naarden, executive vice president and president of Lilly Oncology, this full approval expands the capabilities of Inluriyo in combination with Verzenio, offering a regimen with confirmed benefits that aligns with the clinical practice of changing therapy upon clinical progression. The all-oral combination targets two distinct drivers of tumor growth: on...

Ultragenyx sets $3.95 million price for rare disease gene therapy

Ultragenyx sets $3.95 million price for rare disease gene therapy

By Sriparna Roy and Kamal Choudhury Sept 17 (Reuters) - Ultragenyx Pharmaceutical said on Thursday it has set a U.S. list price of $3.95 million for its newly approved gene therapy Fayuvi, launching one of the world's most expensive drugs as a one-time treatment for a rare, fatal childhood disease.

The Latest: Federal judge orders Kennedy Center to provide 30 days' notice of any building changes

The Latest: Federal judge orders Kennedy Center to provide 30 days' notice of any building changes

A federal judge has ordered the Kennedy Center to provide 30 days’ notice before making any major physical changes to the building, including demolishing it — as President Donald Trump has threatened

Dualitas Therapeutics and Roche Partner to Develop Novel Bispecific Antibodies for Immunology and Inflammation Diseases

Dualitas Therapeutics and Roche Partner to Develop Novel Bispecific Antibodies for Immunology and Inflammation Diseases

Dualitas Therapeutics and Roche Partner to Develop Novel Bispecific Antibodies for Immunology and Inflammation Diseases

EU chief proposes social media ban for kids under 13

EU chief proposes social media ban for kids under 13

European Commission President Ursula von der Leyen has proposed banning children under 13 from accessing social media, online games and chatbots

EU's von der Leyen wants Canada to become bloc's first associate member

EU's von der Leyen wants Canada to become bloc's first associate member

By Julia Payne BRUSSELS, Sept 16 (Reuters) - European Commission President Ursula von der Leyen said on Wednesday she wanted to open the door to Canada becoming the EU's first "associate member," in a significant policy shift alongside plans to forge new links in "an openly hostile world".

Cullinan and Taiho Plan FDA Filing for Lung Cancer Pill Zipalertinib Despite Patient Deaths

Cullinan and Taiho Plan FDA Filing for Lung Cancer Pill Zipalertinib Despite Patient Deaths

Taiho Oncology and Cullinan Therapeutics are moving forward with plans to file for FDA approval of their oral drug candidate, zipalertinib, for non-small cell lung cancer (NSCLC), despite three patient deaths reported during a late-stage study. The Phase 3 REZILIENT3 trial demonstrated that zipalertinib, when combined with chemotherapy, significantly improved progression-free survival (PFS) in patients with first-line advanced non-squamous NSCLC harboring exon 20 mutations to the EGFR gene. Patients receiving the zipalertinib regimen experienced a 50% reduction in the risk of death or disease progression, with a median PFS of 14.5 months compared to 8.5 months in the control group. While adverse events of grade 3 or higher were more frequent in the zipalertinib arm (87% vs. 54.4%), analysts believe the robust efficacy and potential mitigation strategies will outweigh the safety concerns.

OpenAI Explores Canadian Data Center Partnerships Citing Energy and Land Availability

OpenAI Explores Canadian Data Center Partnerships Citing Energy and Land Availability

OpenAI Explores Canadian Data Center Partnerships Citing Energy and Land Availability

European Central Bank President Christine Lagarde Highlights European Investment in U.S. AI Boom

European Central Bank President Christine Lagarde Highlights European Investment in U.S. AI Boom

European Central Bank President Christine Lagarde Highlights European Investment in U.S. AI Boom

Explainer-EU chief wants Canada to become an 'associate member'. What does that mean?

Explainer-EU chief wants Canada to become an 'associate member'. What does that mean?

By Julia Payne BRUSSELS, Sept 16 (Reuters) - European Commission President Ursula von der Leyen said on Wednesday she wanted to open the door for Canada to become the European Union's first "associate member".